» Articles » PMID: 37141141

Artificial Intelligence-enabled Microbiome-based Diagnosis Models for a Broad Spectrum of Cancer Types

Overview
Journal Brief Bioinform
Specialty Biology
Date 2023 May 4
PMID 37141141
Authors
Affiliations
Soon will be listed here.
Abstract

Microbiome-based diagnosis of cancer is an increasingly important supplement for the genomics approach in cancer diagnosis, yet current models for microbiome-based diagnosis of cancer face difficulties in generality: not only diagnosis models could not be adapted from one cancer to another, but models built based on microbes from tissues could not be adapted for diagnosis based on microbes from blood. Therefore, a microbiome-based model suitable for a broad spectrum of cancer types is urgently needed. Here we have introduced DeepMicroCancer, a diagnosis model using artificial intelligence techniques for a broad spectrum of cancer types. Built based on the random forest models it has enabled superior performances on more than twenty types of cancers' tissue samples. And by using the transfer learning techniques, improved accuracies could be obtained, especially for cancer types with only a few samples, which could satisfy the requirement in clinical scenarios. Moreover, transfer learning techniques have enabled high diagnosis accuracy that could also be achieved for blood samples. These results indicated that certain sets of microbes could, if excavated using advanced artificial techniques, reveal the intricate differences among cancers and healthy individuals. Collectively, DeepMicroCancer has provided a new venue for accurate diagnosis of cancer based on tissue and blood materials, which could potentially be used in clinics.

Citing Articles

Using gut microbiome metagenomic hypervariable features for diabetes screening and typing through supervised machine learning.

Chavarria X, Park H, Oh S, Kang D, Choi J, Kim M Microb Genom. 2025; 11(3).

PMID: 40063675 PMC: 11893737. DOI: 10.1099/mgen.0.001365.


Distinctive circulating microbial metagenomic signatures in the plasma of patients with lung cancer and their potential value as molecular biomarkers.

Chen H, Yao X, Yang C, Zhang Y, Dong H, Zhai J J Transl Med. 2025; 23(1):186.

PMID: 39953591 PMC: 11829562. DOI: 10.1186/s12967-025-06209-8.


Techniques for learning and transferring knowledge for microbiome-based classification and prediction: review and assessment.

Han J, Zhang H, Ning K Brief Bioinform. 2025; 26(1.

PMID: 39820436 PMC: 11737891. DOI: 10.1093/bib/bbaf015.


Meta-analysis of gut microbiota alterations in patients with irritable bowel syndrome.

Li X, Li X, Xiao H, Xu J, He J, Xiao C Front Microbiol. 2025; 15():1492349.

PMID: 39777150 PMC: 11703917. DOI: 10.3389/fmicb.2024.1492349.


Machine learning-based analysis identifies and validates serum exosomal proteomic signatures for the diagnosis of colorectal cancer.

Yin H, Xie J, Xing S, Lu X, Yu Y, Ren Y Cell Rep Med. 2024; 5(8):101689.

PMID: 39168094 PMC: 11384723. DOI: 10.1016/j.xcrm.2024.101689.